

## Press Release

**Media Contact**

Martin Kunze  
T +49 6172 609-2115  
martin.kunze@fresenius.com

**Contact for analysts and  
investors**

Dr. Dominik Heger  
T +49 6172 609-2601  
dominik.heger@fmc-ag.com

[www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com)

December 14, 2022

### **Fresenius Medical Care included in Dow Jones Sustainability World Index**

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has entered the Dow Jones Sustainability World Index. Additionally, the company has been included for the 13th time in the Dow Jones Sustainability Index (DJSI) Europe. Fresenius Medical Care achieved an improved rating in most of the evaluated categories, and was awarded maximum scores for its environmental and social reporting. The company was also awarded significantly higher scores in the areas of occupational health and safety, talent attraction and retention, and customer relationship management.

"To us, successful sustainability management means creating lasting economic, environmental and social value," said Helen Giza, CEO of Fresenius Medical Care. "We are proud that the DJSI has recognized our efforts to integrate sustainable actions systematically into our company."

To compile the Dow Jones Sustainability Indexes, the international financial services company S&P Global evaluates the environmental, social and economic performance of companies. The 10 percent of global companies with the highest evaluations form the DJSI World. The DJSI Europe index is composed of the top 20 percent of the companies headquartered in Europe.

You can find an overview of Fresenius Medical Care's progress in sustainability here:

[https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/About\\_us/Sustainability/2021\\_FME\\_Sustainability\\_Highlights.pdf](https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/About_us/Sustainability/2021_FME_Sustainability_Highlights.pdf)

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,153 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at [www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com).

**Disclaimer:**

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.